Andere talen Annovis Bio, Inc.

Aandelen

ANVS

US03615A1088

Beurs gesloten - Nyse Andere beurzen 22:00:02 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
9,85 ^USD	+9,57%		-19,26%	-47,33%

01/04	Annovis kondigt een publicatie aan die het begrip van het werkingsmechanisme van buntanetap bij mensen ondersteunt	CI
29/03	Annovis Bio, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results	02/04
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans	01/04
Annovis Announces Publication That Supports Understanding of Buntanetap?s Mechanism of Action in Humans	01/04
Annovis Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Top Midday Gainers	20/03
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease	20/03
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease	20/03
Annovis Bio, Inc. Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease	20/03
Annovis Bio : Material Event - Form 8-K	20/03
Annovis Bio, Inc. announced that it expects to receive $1.025006 million in funding	15/03
An unknown buyer entered into an agreement to acquire 1.1% stake in Annovis Bio, Inc. for $1 million	15/03
North American Morning Briefing : Fed's Preferred -2-	29/02
Annovis Bio Shares Fall After Downgrade From Brookline Capital	28/02
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024	27/02
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024	27/02
ANNOVIS BIO ANNOUNCES LAST PATIENT LAST VISIT IN THE PHASE II/III STUDY OF BUNTANETAP IN ALZHEIMER'S DISEASE	15/02
Annovis Bio Completes Phase 2 Study of Alzheimer's Treatment Candidate	14/02
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease	14/02
Annovis Bio, Inc. Announces Last Patient Last Visit in Phase II/III Study of Buntanetap in Alzheimer's Disease	14/02
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio	30/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Annovis Bio, Inc.

Aandelen

ANVS

US03615A1088

Andere talen

Filters